Target intelligence / Profile preview

Major histocompatibility complex, class II, DR beta 4 (HLA-DRB4)

Target
HLA-DRB4
Molecular classification
Receptor, Histocompatibility complex (HLA), Immunoglobulin superfamily domain containing
01

Overview

Major histocompatibility complex, class II, DR beta 4 is a membrane-bound heterodimeric protein composed of an alpha (DRA) and a beta (DRB4) chain, primarily expressed on antigen-presenting cells (APCs) such as B lymphocytes, dendritic cells, and macrophages. It binds exogenous peptide antigens from degraded proteins and presents them to CD4+ helper T cells, a key process in adaptive immunity. HLA-DRB4 exhibits polymorphisms that dictate binding specificity for different peptide antigens and is a secondary DR beta chain found associated with certain HLA haplotypes such as DR4, DR7, and DR9. Notably, the DRB4 allele (especially DRB4*01:01) is strongly linked to susceptibility to autoimmune diseases, including type 1 diabetes, by presenting unique self-epitopes to autoreactive T cells. HLA-DRB4 expression and its polymorphisms are routinely assessed in transplantation medicine due to their effect on immune compatibility and graft survival.

Other names
HLA class II histocompatibility antigen, DR beta 4 chainHLA-DRB4MHC class II antigen DRB4DRB4DR-4DR4HLA-DR4B
02

Mechanism of action

Drugs may inhibit or alter antigen presentation, T cell activation, or the immune response (e.g., monoclonal antibodies blocking MHC II-TCR interaction, immunosuppressants reducing surface expression)

03

Biological functions

Immune response (antigen presentation to CD4+ T cells)Signal transduction (by activating helper T cells)
04

Disease associations

Autoimmunity (notably type 1 diabetes, other autoimmune diseases)Lymphoma (modifier role)Potential roles in transplantation outcomes
05

Safety considerations

Potential for enhanced immune activation or, conversely, immune suppression depending on targeting strategyRisk of autoimmunity through presentation of self-antigens leading to autoreactive T cell responsesPossible graft rejection in transplant settings when not optimally matched
06

Interacting drugs

Specific drugs directly interacting with HLA-DRB4 are not listed in available sources; in general, immunomodulatory drugs (e.g., monoclonal antibodies, immunosuppressives) may affect processes involving MHC class II molecules
07

Biomarkers

HLA-DRB4 typing is used in transplantation to improve donor selection and reduce rejection riskPresence of HLA-DRB4 alleles (e.g. DRB4*01:01) is associated with greater risk of autoimmune disease, notably type 1 diabetes

Beyond the preview

Go deeper on Major histocompatibility complex, class II, DR beta 4 (HLA-DRB4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Major histocompatibility complex, class II, DR beta 4 (HLA-DRB4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call